Josiah K. Halm, M.D., M.S., FACP, FHM, CMQ
Department of Hospital Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Hospital Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Chair ad interim, Department of Hospital Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2003 | Medical College of Wisconsin, Milwaukee, WI, USA, MS, Clinical Epidemiology |
| 1996 | University of Ghana Medical School, Accra, GHA, MB.chB, Medicine |
Postgraduate Training
| 2014-2016 | Certificate Program in the Section of Integrated Ethics, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2006-2006 | Fellowship, 32nd Epidemiology and Prevention of Cardiovascular Disease, American Heart Association, Tahoe City, CA |
| 2001-2003 | Primary Care Research & Faculty Development, Medical College of Wisconsin, Milwaukee, WI |
| 1998-2001 | Residency, Internal Medicine, Cook County Hospital, Chicago, IL |
| 1996-1997 | Housemanship, Internal Medicine & Ob/Gyn, Korle-bu Teaching Hospital, Accra |
Licenses & Certifications
| 2013 | The American Board of Medical Quality |
| 2001 | Diplomat, American Board of Internal Medicine (ABIM) |
Experience & Service
Faculty Academic Appointments
Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2020
Associate Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020
Assistant Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2014
Administrative Appointments/Responsibilities
Associate Director, Department of Faculty Diversity, Equity & Inclusion, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2021
Clinical Medical Director, Clinical Decision Unit (CDU), The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2015
Director of Hospitalist Program, Aurora Sinai Medical Center, Milwaukee, WI, 2005 - 2008
Other Professional Positions
Adjunct Associate Professor, Department of Medicine, Baylor College of Medicine, Volunteer Clinical Faculty, Houston, TX, 2015 - 2016
Section Chief, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2020
Institutional Committee Activities
Member, Clinical Faculty Review Committee (CFRS), 2022 - Present
Member, Provider Communications Advisory Board, 2022 - Present
Member, Faculty DEI Committee, 2021 - 2023
Member (ex-officio), Committee on Faculty Awards, 2021 - Present
Member, Cost of Care Committee, 2021 - Present
Member, Hospital at Home Committee, 2021 - Present
Member, Institutional CV Committee, 2019 - Present
Member, Africa Committee, 2016 - Present
Member, Institutional Patient Safety Committee, 2015 - Present
Alternate Member, Accreditation Alternatives Committee, 2014 - 2014
Member, Clinical Effectiveness Committee, Venous Thromboembolism (VTE) Treatment Algorithm Subcommittee, 2013 - Present
Member, Clinical Effectiveness Committee, Venous Thromboembolism (VTE) Prophylaxis Algorithm and Order Set Committee, 2013 - Present
Alternate Member for Department Chair, Acute and Critical Care Services Subcommittee, 2013 - 2015
Member, Admissions Review Committee, 2012 - Present
Member, Quality Improvement Assessment Board (QIAB), 2011 - Present
Member, Ongoing Professional Practice Evaluation/Focus Professional Practice Evaluation (OPPE/FPPE) Quality Officers, 2010 - Present
Member, Division of Internal Medicine Quality Council, 2009 - Present
Honors & Awards
| 2019 - Present | Member, American Board of Medical Quality |
| 2017 | Division Quality Award |
| 2015 | 2015 Top Hospitalists, TOP DOCS, American College of Physicians (ACP) |
| 2014 | Clinical Leader of the Year Award, The University of Texas MD Anderson Cancer Center, Division of Internal Medicine, November |
| 2013 | Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center |
| 2012 | Heart of Leadership 2012 Graduate, The University of Texas MD Anderson Cancer Center |
| 2012 | Best Speaker Award, The University of Texas MD Anderson Cancer Center, Department of General Internal Medicine Conference |
| 2012 - Present | Quality and Safety Educators Academy Graduate, Society of Hospital Medicine |
| 2010 - 2011 | Glycemic Control Mentored Implementation Program 2010/2011, Society of Hospital Medicine |
| 2010 - 2012 | Venous Thromboembolism Prevention Collaborative Mentored Implementation Program, Society of Hospital Medicine |
| 2009 | Clinical Safety and Effectiveness (CS&E) Graduate/Project Facilitator, The University of Texas MD Anderson Cancer Center |
| 2006 - Present | Cardiovascular Disease Epidemiologist, American Heart Association (AHA) |
| 2005 - 2015 | Specialist, Clinical Hypertension, American Society of Hypertension (ASH) |
Professional Memberships
Grant & Contract Support
| Date: | 2015 - 2017 |
| Title: | Derivation and Validation of a Readmission Risk Scoring System in Cancer Patients |
| Funding Source: | University of Texas Healthcare and Effectiveness Quality of Care Grants Program |
| Role: | Co-Principal Investigator |
| ID: | Grant 162291 |
| Date: | 2007 - 2008 |
| Title: | Double Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure [ASCEND-HF] |
| Funding Source: | Aurora Sinai Medical Center |
| Role: | Principal Investigator |
| Title: | A Phase I study to Evaluate the Safety of Dose Escalation of Compound Kushen Injection (ZD023) in Lung/Head and Neck Patients receiving Stereotactic Body Radiation Therapy |
| Funding Source: | |
| Role: | Collaborator |
| ID: | Protocol 2021-000 |
| Title: | Expanded Access to Convalescent Plasma for the Treatment of Patients with Covid 19 |
| Funding Source: | |
| Role: | Collaborator |
| Title: | Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Covid 19 Related Acute Respiratory Distress Syndrome |
| Funding Source: | IND# 19950 |
| Role: | Collaborator |
| ID: | Phase I/II Protocol IRB 2020-0365 |
| Title: | Pul0942 in Reducing Infection Rate Progression to Covid 19. A Phase 2 Multiple Dose study to Evaluate the Efficacy and Safety of Uul0942 Inhalation Solution in Reducing the Infection Rate and Progression to Covid 19 in Adults Exposed to SAR CoV 2 |
| Funding Source: | IND# 148628 |
| Role: | Collaborator |
| ID: | IRB ID#2020-0407 |
| Title: | Implementation of Digital Vital Sign Monitoring to Decrease Sleep Interruption and Enhance Recovery in Phase II of the Promoting Sleep |
| Funding Source: | Patient Engagement and Recovery (PROSPER) Project |
| Role: | Collaborator |
| Title: | External Validation of the Covid 19 Risk in Oncology Evaluation Tool |
| Funding Source: | CORONET validation |
| Role: | Collaborator |
| Title: | Developing a model to enhance emotional wellbeing in adult oncology - NIH Grant #13086045, The University of Texas MD Anderson Cancer Center |
| Funding Source: | NIH |
| Role: | Principal Investigator |
| ID: | Application No: 4430715 |
| Title: | The TEXAS Project: Transitions Explored and Studied: Leveraging Data to Prevent Readmissions in the TMC |
| Funding Source: | TMC Health Policy Institute Review Committee |
| Role: | Co-Principal Investigator |
Selected Publications
Peer-Reviewed Articles
- Manzano JM, Muthu M, Kheder E, Mohammed A, Halm J, Dickson K, Ali N, Leung C, Koom-Dadzie K, Rubio D, Odaro O, Sibille M, Etchegaray M, Wilson K, Lin H, George M. Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center. Support Care Cancer 30(9):7783-7788, 2022. e-Pub 2022. PMID: 35705751.
- Manzano JM, Lin H, Zhao H, Halm JK, Suarez-Almazor ME. Derivation and Validation of the Cancer READMIT Score: A Readmission Risk Scoring System for Patients With Solid Tumor Malignancies. JCO Oncol Pract 18(1):e117-e128, 2022. e-Pub 2021. PMID: 34357793.
- Jones SL, Cheon O, Manzano JM, Park AK, Lin HY, Halm JK, Baek J, Graviss EA, Nguyen DT, Kash BA, Phillips RA. Comparison of LACE and HOSPITAL Readmission Risk Scores for CMS Target and Nontarget Conditions. Am J Med Qual 37(4):299-306, 2022. e-Pub 2021. PMID: 34935684.
- Litwin RJ, Tam AL, Sheth RA, Yevich SM, Chan JL, Jazaeri AA, Halm JK, Gupta S, Huang SY. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction. Abdom Radiol (NY) 46(9):4489-4498, 2021. e-Pub 2021. PMID: 33999283.
- Manzano JG, Park A, Lin H, Liu S, Halm JK. Demonstrating value: association of cost and quality outcomes with implementation of a value-driven oncology-hospitalist inpatient collaboration for patients with lung cancer. BMJ Open Qual 8(1):e000381, 2019. e-Pub 2019. PMID: 30997414.
- Manzano JG, Gadiraju S, Hiremath A, Lin HY, Farroni J, Halm J. Unplanned 30-Day Readmissions in a General Internal Medicine Hospitalist Service at a Comprehensive Cancer Center. J Oncol Pract 11(5):410-5, 2015. e-Pub 2015. PMID: 26152375.
- Elting LS, Chang YC, Parelkar P, Boers-Doets CB, Michelet M, Hita G, Rouleau T, Cooksley C,Halm J, Vithala M, Bossi P, Escalante C, Brennan MT, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer 21(11):3243-54, 2013. e-Pub 2013. PMID: 23636648.
- Halm J, Amoako E. Physical activity recommendation for hypertension management: Does healthcare provider advice make a difference?. Ethn Dis 18(3):278-82, 2008. PMID: 18785439.
Invited Articles
- Jones, S, Manzano J, Halm, J, et al. Comparison of LACE and HOSPITAL Readmission Scores for CMS Target and Non-Target Conditions. American Journal of Medical Quality (on-line print) AJMQ-21-200RI, 2021.
- Qdaisat A, Yeung SJ, Variyam DE, Badugu P, Ghaly F, Rice TW, Halm JK, Carter BW, Sun J, Gonzalez CE, Viets-Upchurch J, Steele JR, Wu CC. Evaluation of Cancer Patients With Suspected Pulmonary Embolism: Performance of the American College of Physicians Guideline. J Am Coll Radiol 17(1 Pt A):1-9, 2020. e-Pub 2019. PMID: 31376398.
Abstracts
- Robert J. Litwin, Alda L. tam, Rahul A. Sheth, Steven M. Yevich, Johanna L. Chan, Amir A. Jazeri, Josiah K. Halm, Sanjay Gupta, Steven Y. Huang. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction. Abdominal Radiology https://doi.org/10.1007/s00261-021-03115-7, 2021.
- N Brito-Dellan, P Gaudel, J Halm. Onco-Hospitalist and Their Increasing role in Cancer Patient Care. Supportive Care in Cancer:S83, 2021.
- Carmen Escalante*, Ali Zalpour, Juhee Song, Marsha Richardson, Josiah Halm, S. Wamique Yusuf, Terry Rice. Adverse Events of Rivaroxaban Usage in Younger versus Older Cancer Patients MASCC20-ABS-1195, Annual Meeting, (accepted) Seville Spain, 2020.
- Joanna-Grace Manzano, Anne Park, Heather Lin, Suyu Liu, Josiah Halm. Demonstrating Value: Association of Cost and Quality Outcomes With Implementation of a Value-Driven Oncology-Hospitalist Inpatient Collaboration for Patients With Lung Cancer. BMJ Open Quality 8:e000381.doi:10 1136/bmjoq, 2019.
- Manzano, F, Halm, J, et al. Readmission Among Patient With Cancer Who Were Discharges With Hospice Care. Journal of Clinical Oncology, 25 (suppl 8S, abstract 46), 2017.
- JG Manzano, AG Barbo, HY Lin, H Zhao, J Halm, ME Suarez-Almazor. Readmission Among Patients with Cancer Who Were Discharged with Hospice Care. Journal of Clinical Oncology 35((8_suppl)):46, 2017.
- CP Escalante, YC Chang, K Liao, T Rouleau, J Halm, P Bossi. Meta-Analysis of Cardiovascular Toxicity Risks in Cancer Patients on Selected Targeted Agents. Supportive Care in Cancer 24(9):4057-4074, 2016.
- CP Escalante, LS Elting, H Halm, ME Suarez-Almazor. Meta-Analysis: Risk of Congestive Heart Failure (CHF) in Selected Targeted Agents. Journal of Clinical Oncology 33(29_suppl):64-68, 2015.
- 2014 ASCO Quality Care Symposium. Utilizing TQM and CQI Principles in Establishing a Type1 Observation Unit in a Comprehensive Cancer Center Boston, MA, 2014.
- A Hiremath, JG Manzano, J Halm||M, J Farroni. Augmentation of Cancer Outcomes Through Safe Transitions. Journal of Clinical Oncology 32((30_suppl)):250, 2014.
- Halm J, Amoako EP. Physical Activity Recommendation for Hypertension Management: Does Healthcare Provider Advice Make a Difference?. Ethnicity and Disease (International Society of Hypertension in Blacks, 2008.
- Jordan J, Halm J, et al. Benefits of Initiating a Hospitalist PICC Program - Experience from an Academic Community Medical Center. Journal of Hospital Medicine 3(1):62, 2008.
- Reiss M, Halm J. Lead Poisoning in an Adult: Lead Mobilization by Pregnancy?. JGIM(22):1212-1215, 2007.
- Halm J. Using electronic medical records to help improve control of hypertension: Secondary database analysis of blood pressure in a large healthcare system in Wisconsin. JCH 8:A215, 2006.
- Halm J, Schapira M, Grimm C et al. Do physicians' recommend exercise in adults with hypertension and do patients follow their advice? Ethnicity & Disease 14:S2-58, 2004.
- Halm J, Scheidermayer D, Sebastian J et al. The times…they are achanging: Survey of winners of best teacher award in a department of medicine. JGIM(18):243, 2003.
- C. P. Escalante; A. Zalpour; J Song; M. Richardson; J. Halm; S. W. Yusuf; S, Gao. Adverse Events of Rivaroxaban Usage in Cancer Patients. Internal Conference on Thrombosis & Hemostasis, Bergamo, Italy:S220-S221.
- Manzano, F, Halm, J, et al. Evaluating the Impact of Oncology-Hospitalist Model of Inpatient Care on Unplanned 30-Day Readmissions Among Patients with Lung Cancer. 2017 NCCN 22nd Annual Conference, Orlando, FL.
- CP Escalante, MD, A Zalpour, PharmD, J Song, PhD, M Richardson, MSW, T Lam, PhD, J Halm, MD, SW Yusuf, MD, S Gao, MD. Practice Patterns and Outcomes of Rivaroxaban Usage in Cancer Patients. ASCO 2016 Conference.
- Halm JK. Hospitalization Outcomes Among Patients with Confirmed and Suspected Covid 19 - D# CODE.
- Halm J. AKI and Clinical Outcomes on Cancer Patient with Normal Renal Function and Prior CKD who Acquired Covid 19 Infection. ASCO 2021.
Book Chapters
- Halm J. Chapter 5: Acute Gastro-Intestinal Bleeding. In: Oncologic Emergencies. Springer Science: New York.
- Gonzalez, C; Halm J. Constipation in Cancer Patients. In: Oncologic Emergency Medicine. Springer Science: New York.
Patient Reviews
CV information above last modified June 24, 2024